Iptacopan

Pre-clinicalActive

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

C3 Glomerulopathy (C3G)

Conditions

C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH)

Trial Timeline

— → —

NCT ID

NCT05222412

About Iptacopan

Iptacopan is a pre-clinical stage product being developed by Novartis for C3 Glomerulopathy (C3G). The current trial status is active. This product is registered under clinical trial identifier NCT05222412. Target conditions include C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH).

What happened to similar drugs?

0 of 1 similar drugs in C3 Glomerulopathy (C3G) were approved

Approved (0) Terminated (0) Active (1)

🔄LNP023NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05222412	Pre-clinical	Active	—	—	C3 Glomerulopathy (C3G)
NCT06994845	Phase 3	Recruiting	Nov 27, 2025	Jun 30, 2030	Primary Immunoglobulin A Nephropathy (IgAN)
NCT06903234	Pre-clinical	Active	Mar 31, 2025	Oct 1, 2029	Hemoglobinuria, Paroxysmal
NCT06797518	Phase 2	Recruiting	Feb 21, 2025	Nov 27, 2027	Glomerulonephritis, IGA
NCT06517758	Phase 3	Recruiting	Jul 31, 2024	May 27, 2032	Generalized Myasthenia Gravis
NCT05935215	Phase 3	Recruiting	Feb 28, 2024	Jul 19, 2029	Atypical Hemolytic Uremic Syndrome
NCT05630001	Phase 3	Completed	Apr 24, 2023	Oct 17, 2024	Paroxysmal Nocturnal Hemoglobinuria
NCT04889430	Phase 3	Active	Jan 17, 2022	Aug 13, 2026	Atypical Hemolytic Uremic Syndrome
NCT05086744	Phase 2	Terminated	Dec 21, 2021	May 17, 2024	Immune Thrombocytopenia (ITP)
NCT04747613	Phase 3	Active	Jul 27, 2021	Oct 19, 2027	Paroxysmal Nocturnal Hemoglobinuria
NCT03439839	Phase 2	Completed	Apr 9, 2018	Feb 28, 2022	Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis

Competing Products

5 competing products in C3 Glomerulopathy (C3G)

See all competitors

Product	Company	Stage	Hype Score
LNP023	Novartis	Phase 3	47
Avacopan + Avacopan Matching Placebo	Amgen	Phase 2	35
ARO-C3 + Placebo	Arrowhead Pharmaceuticals	Phase 1/2	29
BCX9930	BioCryst Pharmaceuticals	Phase 2	21
OMS906 study drug	Omeros Corporation	Phase 2	36